For Eye Care Professionals
Bausch + Lomb Launches Alaway® Preservative Free Antihistamine Eye Drops
Prevent Blindness and Bausch + Lomb to Launch Year-Long Video Series to Raise Awareness of Age-Related Macular Degeneration (AMD)
Bausch + Lomb Announces Scientific Data on Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses to be Presented at the Virtual Global Specialty Lens Symposium
Bausch + Lomb Completes Enrollment of First Phase 3 Study For NOV03 (perfluorohexyloctane)
Bausch Health Initiates Second Phase 3 Study for NOV03 Investigational Treatment for Dry Eye Disease Associated With Meibomian Gland Dysfunction
Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Materials Recycled Through ONE by ONE Recycling Program
Bausch + Lomb Highlights Surgical, Pharmaceutical and Consumer Health Care Innovations and New Business Ventures; Offers Educational Opportunities During The Annual Meeting of The American Academy of Ophthalmology
Bausch + Lomb Introduces SimplifEYE™ IOL Delivery System for enVista® Toric and Monofocal Preloaded Intraocular Lenses
Bausch + Lomb Announces New Scientific and Clinical Analyses to be Presented on Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses During the American Academy of Optometry Annual Meeting
Nielsen’s BASES Names LUMIFY® Eye Drops To 2020 U.S. BASES Top 25 Breakthrough Innovations List
FDA Approves Bausch + Lomb Alaway® Preservative Free (Ketotifen Fumarate) Ophthalmic Solution, 0.035%
Bausch + Lomb Launches Innovative Bausch + Lomb INFUSE™ Silicone Hydrogel (Sihy) Daily Disposable Contact Lenses
Bausch + Lomb Launches -2.75 Cylinder For Biotrue® ONEday For Astigmatism Daily Disposable Contact Lenses
Bausch + Lomb Introduces Pinnacle 360™ 25-gauge Scleral Fixation Forceps
Bausch + Lomb Licenses Orthokeratology Lens System from Katt Design Group
FDA Provides 510(k) Clearance for Bausch + Lomb INFUSE™ Daily Disposable Silicone Hydrogel (SiHy Daily) Contact Lenses
Bausch + Lomb Licenses Exclusive Rights from STADA and Xbrane to a Biosimilar Candidate for Lucentis (ranibizumab) in the United States and Canada
Bausch + Lomb Announces Publication of 10-Year ARMOR Study Results on Ocular Antibiotic Resistance in JAMA Ophthalmology
Prevent Blindness and Bausch + Lomb to Join Together to Raise Awareness and Provide Educational Resources for February’s Age-related Macular Degeneration Awareness Month
Bausch + Lomb and Clearside Biomedical Announce Publication of Pivotal Phase 3 Data on XIPERE™(Triamcinolone Acetonide Suprachoroidal Injectable Suspension) in Opthalmology